A pill called daraxonrasib left pancreatic tumours undetectable on CT scans in about 8% of patients in a trial involving people whose cancer had spread to other organs, offering encouraging evidence against a disease with exceptionally poor survival rates.
The study involved 61 patients recently diagnosed with advanced pancreatic cancer. Tumour growth stopped in 90%, while just over 60% saw their tumours shrink or disappear. Doctors cautioned that the treatment cannot yet be considered a cure: they do not know how long it can keep the disease under control.
A year after treatment began, 76.6% of participants were alive, compared with the usual 40–45% among patients receiving chemotherapy alone. Patients had a median follow-up of 18 months, and some whose cancer became undetectable had not seen it return during that period. Longer studies will examine whether lasting remission is possible.
Daraxonrasib is a KRAS inhibitor. It locks on to and switches off certain mutations, found in most pancreatic cancers, that drive tumour growth. Similar mutations occur in dozens of other cancers, prompting hopes that the approach could eventually have wider uses.
Dr Wungki Park, a gastrointestinal medical oncologist at Memorial Sloan Kettering Cancer Center in New York, presented the findings at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona. He said he had never seen so many tumours disappear in patients whose cancer had spread.
“We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival,” he said.
The distinction between a tumour disappearing on a scan and a lasting cure remains crucial. Even without full remission, doctors believe the treatment could give patients more time.
Pancreatic cancer has the lowest survival rate of all common cancers in the UK, with a similarly poor prognosis globally. Half of those diagnosed die within three months; when it has spread to other organs, only about 3% survive five years.
Michelle Mitchell, Cancer Research UK’s chief executive, described the results as the biggest leap forward for pancreatic cancer patients in decades, while stressing that survival remains very low. More trials are needed before the treatment can be assessed for NHS use, and its long-term effectiveness remains unresolved.









Join the conversation